WILMINGTON, DE — Incyte (Nasdaq: INCY) reported strong early-stage clinical results for an experimental precision antibody that sharply reduced disease markers in patients with essential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback